Rhumbline Advisers Purchases 6,153 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Rhumbline Advisers boosted its stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 31.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,920 shares of the company’s stock after acquiring an additional 6,153 shares during the quarter. Rhumbline Advisers owned 0.06% of Kyverna Therapeutics worth $97,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC bought a new stake in Kyverna Therapeutics in the 3rd quarter valued at $33,000. China Universal Asset Management Co. Ltd. bought a new stake in Kyverna Therapeutics in the 4th quarter valued at $34,000. Creative Planning bought a new stake in Kyverna Therapeutics in the 3rd quarter valued at $54,000. Jacobs Levy Equity Management Inc. bought a new stake in Kyverna Therapeutics in the 3rd quarter valued at $97,000. Finally, BNP Paribas Financial Markets lifted its position in Kyverna Therapeutics by 2,166.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company’s stock valued at $133,000 after acquiring an additional 25,997 shares in the last quarter. 18.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on KYTX. HC Wainwright lowered their price target on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. Wells Fargo & Company lowered their price target on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $18.40.

Kyverna Therapeutics Trading Down 2.7 %

Shares of KYTX opened at $2.53 on Tuesday. Kyverna Therapeutics, Inc. has a 52 week low of $2.50 and a 52 week high of $30.60. The firm’s 50-day simple moving average is $3.19 and its 200 day simple moving average is $4.64.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.